Fig. 3.
Fig. 3. Role of the enhancer and GATA elements in the human and murine promoter activities. / Transcriptional activities were analyzed in HEL, K562, and LIN-175 cell lines as described in Figure 2. (A) The murine −538 and −396 GPIIb promoter constructs, extending from −538 and −396 to +32 respectively, were first analyzed. The human −598/−406 enhancer fragment generated by PCR and sequenced was inserted in direct or reverse orientation upstream from the murine −396 GPIIb promoter fragment. A disrupting mutation was introduced into the murine −456 GATA site of the murine −899 GPIIb promoter construct. Activity of this mutated promoter (−899 mG*) was compared with that of the wild-type (−899 WT) murine promoter. (B) The murine chimeric (−899* hGATA) construct with hGATA region (open box) and the human 813 chimeric (−813* mGATA) construct with mGATA region (gray-filled box) were transfected in HEL, K562, and LIN-175 cells. CAT activities are compared with that of the wild-type murine and human GPIIb promoter constructs as described in Figure 2.

Role of the enhancer and GATA elements in the human and murine promoter activities.

Transcriptional activities were analyzed in HEL, K562, and LIN-175 cell lines as described in Figure 2. (A) The murine −538 and −396 GPIIb promoter constructs, extending from −538 and −396 to +32 respectively, were first analyzed. The human −598/−406 enhancer fragment generated by PCR and sequenced was inserted in direct or reverse orientation upstream from the murine −396 GPIIb promoter fragment. A disrupting mutation was introduced into the murine −456 GATA site of the murine −899 GPIIb promoter construct. Activity of this mutated promoter (−899 mG*) was compared with that of the wild-type (−899 WT) murine promoter. (B) The murine chimeric (−899* hGATA) construct with hGATA region (open box) and the human 813 chimeric (−813* mGATA) construct with mGATA region (gray-filled box) were transfected in HEL, K562, and LIN-175 cells. CAT activities are compared with that of the wild-type murine and human GPIIb promoter constructs as described in Figure 2.

Close Modal

or Create an Account

Close Modal
Close Modal